(CercleFinance.com) – AstraZeneca gained more than 2.5% on the British stock market on Tuesday after the announcement of the success of a clinical trial in the treatment of prostate cancer.
Shortly after the opening, the title rose 2.6%, signing the third best performance of a FTSE 100 index up 0.3%.
The biopharmaceutical group announced this morning that the drug Lynparza combined with the cancer drug abiraterone had made it possible to “significantly” improve the survival of patients.
In detail, the phase III clinical study, called ‘PROpel’, demonstrated that the combination of the two molecules reduced the risk of disease progression by 34% compared to the reference treatment.
These results relate more specifically to the first-line treatment of metastatic castration-resistant prostate cancer.
In its press release, AstraZeneca recalls that prostate cancer is the second most common in men, with nearly 375,000 deaths each year.
The laboratory has planned to present these data on Thursday at the ASCO symposium devoted to cancers of the genitourinary tract.
Copyright (c) 2022 CercleFinance.com. All rights reserved.